NasdaqGM:CRVSBiotechs
Corvus Pharmaceuticals (CRVS) Is Up 7.3% After Promising Soquelitinib Data And Extended Cash Runway
In recent months, Corvus Pharmaceuticals reported encouraging Phase 1 results for its oral ITK inhibitor soquelitinib in atopic dermatitis, showing early efficacy signals alongside a clean safety profile and extending its cash runway into the second quarter of 2028.
These developments, coupled with upbeat coverage from investment commentators highlighting soquelitinib’s potential to compete in immunology and attract larger partners, have drawn fresh attention to Corvus’s pipeline and funding...